cancer doctors

Endometrial Cancer Treatment

Question: Is tamoxifen a must for ER/PR negative menstruating lady for breast cancer treatment? i m 32 years old treated for breast cancer 1 year before and was advised tamoxifen. since i had endometrial hyperplasia, tamoxifen was stopped and started letrozol. now i m advised to stop that also and go back to tamoxifen, ER/PR negative. what can be done?

Answer: Tamoxifen (also known as Nolvadex) is a synthetic compound similar to estrogen. It mimics the action of estrogen on the bones and uterus, but blocks the effects of estrogen on breast tissue. Tamoxifen is used as adjuvant hormonal therapy immediately after surgery in early stages of breast cancer and in advanced metastatic breast cancer (stages III and above) in women. Tamoxifen belongs to a family of compounds called antiestrogens. Antiestrogens are used in cancer therapy to inhibit the effects of estrogen on target tissues. Estrogen is a steroid hormone secreted by the female ovary. Depending on the target tissue, estrogen can stimulate the growth of female reproductive organs and breast tissue, play a role in the female menstrual cycle, and protect against bone loss by binding to estrogen receptors on the outside of cells within the target tissue. Antiestrogens act selectively against the effects of estrogen on target cells in a variety of ways, thus they are called selective estrogen receptor modulators (SERMs). Depending on various health factors and improvement of the patient antiestrogens are stopped and started again. I feel your Oncologist might have felt the necessity to stop and then again resume Tamoxifen in your case. It is in order to give negative menstruating breast cancer patients. Hence you may take it as advised by your doctor. Best of luck. - Addition - The reason for Tamoxifen may be because ER/PR+/HER2- cancers are often not extremely responsive to chemotherapy. However, they generally do respond to Tamoxifen.-


Endometrial Cancer Treatment News

Pricey surgery robots lack clear benefits: study

Reuters
In the latest study to cast doubt on the technology, researchers found similar complication rates among women treated for endometrial cancer whether or not surgeons got help from a robot. Yet robotic surgery costs about $1300 more than the low-tech ...
 

Benitec Biopharma and Medistem Technologies Successfully Combined in ...

MarketWatch (press release)
About Medistem Medistem Inc. is a biotechnology company developing technologies related to adult stem cell extraction, manipulation, and use for treating inflammatory and degenerative diseases. The company's lead product, the endometrial regenerative ...
 

Robotic Surgery: Ready for Prime Time in Endometrial Cancer?

Medscape
Researchers compared perioperative morbidity, resource use, and the cost of laparoscopic and robotic hysterectomy in 2464 women with endometrial cancer, and found that robotic hysterectomy offers little short-term benefit.
 

The Link Between Obesity and Endometrial Cancer

Medscape
It is well known that progesterone (found in the combined contraceptive pill or in oral or intrauterine progesterone therapy) can be used both to protect against and treat endometrial hyperplasia and cancer. Weight loss, and therefore loss of adipose ...
 

Wonder Woman

Walk to increase longivity
Wonder Woman
 

Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to ...

Sacramento Bee
The report extensively analyses their 177 identified drug targets, organized into 170 drug target strategies, and assesses them in 70 cancer indications. BioSeeker has applied its unique drug assessment methodology to stratify the angiogenesis ...
 

Similar Morbidity for Robotic, Laparoscopic Hysterectomy

Doctors Lounge
While complication rates are similar between robotic and laparoscopic hysterectomies for the treatment of endometrial cancer, robotic treatment is significantly more costly than laparoscopic treatment, according to a study published online Jan.
 

Another Year, Another High...

NASDAQ
Ariad's out-licensed product candidate Ridaforolimus is under development for multiple oncology indications, including soft tissue/bone sarcomas, endometrial cancer, breast cancer, lung and colon cancers, ovarian cancers and kidney cancer.
 

Proactive Investors USA & Canada

Drug maker Aeterna Zentaris posts positive trial results for cancer drug
Proactive Investors USA & Canada
 

Rediff

Cancer - Know Your Chances
AllAfrica.com
 

Types of Cancer


Adrenal Cancer Anal Cancer Brain Cancer Colorectal Cancer Endometrial Cancer Esophageal Cancer
Esophageal Cancer Laryngeal Cancer Oral Cancer Penile Cancer Prostatic Cancer Stomach Cancer
Thyroid Cancer Bladder Cancer Bone Cancer Cervix Cancer Heart Cancer Kidney Cancer
Melanoma Cancer Pancreas Cancer Asbestos Cancer